ReviewFrontiers in genetics2018
CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities.
Review in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- JAK3-deficient mini-pigs exhibit impaired lymphoid organogenesis, intestinal structure, and leukocyte/cytokine production.Journal of advanced research · 2026Article
- Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics.European journal of nuclear medicine and molecular imaging · 2025Review
- Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering.The CRISPR journal · 2023Article
- Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).Oncology letters · 2023Review
- Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.Current oncology (Toronto, Ont.) · 2023Review
- Nebulous without white: annotated long-read genome assembly and CRISPR/Cas9 genome engineering in Drosophila nebulosa.G3 (Bethesda, Md.) · 2022Article
- Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application.Human genetics · 2022Review
- CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.Molecular biotechnology · 2021Review
- Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications.International journal of molecular sciences · 2021Review
- Application of CRISPR/Cas System in the Metabolic Engineering of Small Molecules.Molecular biotechnology · 2021Review
- Alternative Animal Models of Aging Research.Frontiers in molecular biosciences · 2021Review
- Recent Advances in the Application of CRISPR/Cas9 Gene Editing System in Poultry Species.Frontiers in genetics · 2021Review
- Human Organoid and Supporting Technologies for Cancer and Toxicological Research.Frontiers in genetics · 2021Review
- HK022 bacteriophage Integrase mediated RMCE as a potential tool for human gene therapy.Nucleic acids research · 2020Article
- Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.Plant biotechnology journal · 2020Review
- Prime Editing Technology and Its Prospects for Future Applications in Plant Biology Research.Biodesign research · 2020Review
- Decision-Making in Cascade Complexes Harboring crRNAs of Altered Length.Cell reports · 2019Article
- Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights.Genes · 2019Review
- Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases.BioMed research international · 2019Review
- Application of new biotechnologies for improvements in swine nutrition and pork production.Journal of animal science and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and Cascade 9 (also known as Cas9, CRISPR associated protein 9) confer protection against invading viruses or plasmids. The CRISPR/Cascade 9 system constitutes one of the most powerful genome technologies available to researchers today. So far, this technology has enabled efficient genome editing and modification in several model organisms and has successfully been used in biomedicine and biomedical engineering. However, challenges for efficient and safe genetic manipulation in several organisms persist. Here, we review functional approaches and future challenges associated with the use of the CRISPR/Cascade 9 genome editing system and discuss opportunities, ethical issues and future directions within this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.